Trade Names:Mylotarg- Powder for injection, lyophilized 5 mg (protein equivalent) per vial
Chemotherapy agent composed of a recombinant humanized immunoglobulin G 4 kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium. The antibody portion of gemtuzumab ozogamicin binds specifically to the CD33 antigen, which is expressed on the surface of leukemic blasts in patients with acute myeloid leukemia (AML). This ultimately results in DNA double-strand breaks and cell death.
AUC doubles after second dose.
Many metabolites found in liver microsomes, cytosol, and HL-60 promyelocytic leukemia cells.
First dose t ½ is about 40 h (total), 140 h (unconjugated). Second dose t ½ is about 60 h (total).
CD33-positive AML in first relapse in patients at least 60 yr of age who are not candidates for other antineoplastics.
IV 9 mg/m 2 /dose for a total of 2 doses, given on days 0 and 14. The second dose may be given in the absence of full hematologic recovery.
Total max time allowed for storage of reconstituted and diluted solution and completion of infusion is 20 h, consisting of reconstitution at 2 h or less at room temperature or refrigeration, dilution at 16 h or less at room temperature, and administration over a 2-h infusion.
Store unopened vials in refrigerator (36° to 46°F). Protect from light.
Coadministration of drugs with similar pharmacologic effects may cause additive adverse reactions, including toxicity.
None well documented.
Hypotension (20%); hypertension (16%); hemorrhage (11%); tachycardia (10%); venoocclusive disease (5%).
Headache (37%); dizziness, insomnia (12%); depression (9%); anxiety (8%).
Cutaneous herpes simplex (21%); rash (18%); pruritus (6%).
Epistaxis (28%); pharyngitis (12%); rhinitis (8%).
Nausea (68%); vomiting (58%); diarrhea (32%); anorexia, oral mucositis, stomatitis (25%); constipation (23%); dyspepsia (10%); gum hemorrhage (9%).
Vaginal hemorrhage (4%); metrorrhagia (3%).
Thrombocytopenia (treatment phase: 99% experienced grade 3 or 4; treatment emergent: 49% experienced grade 3 or 4); neutropenia (treatment phase: 98% experienced grade 3 or 4); anemia (treatment phase: 52% experienced grade 3 or 4; treatment emergent: 14% experienced grade 3 or 4); leukopenia (47%); petechiae (19%); neutropenic fever (17%); ecchymosis (10%).
Hyperbilirubinemia (29%); abnormal LFTs (24%); elevated AST (18%); elevated ALT (9%).
Hypokalemia (26%); increased LDH (16%); peripheral edema (14%); bilirubinemia (12%); hyperglycemia, hypocalcemia (10%); hypophosphatemia, increased alkaline phosphatase (8%); hypomagnesemia (6%).
Back pain (14%); myalgia (6%).
Dyspnea (26%); increased cough (17%); pneumonia (13%); pulmonary physical findings (9%).
Fever (82%); chills (66%); asthenia (36%); abdominal pain (32%); infection (treatment phase: 30% experienced grade 3 or 4; treatment emergent: 9%); sepsis (26%); local reaction (22%); pain (18%); neutropenic fever (17%); bleeding events (treatment phase: 13% experienced grade 3 or 4); hypoxia (5%).
Administer under supervision of a health care provider experienced in treatment of acute leukemia and in facilities equipped to monitor and treat such patients.Hypersensitivity/Anaphylaxis
Severe hypersensitivity (including anaphylaxis) and other infusion-related reactions, including severe pulmonary reactions, may occur. Infrequently, these events may be fatal. In most cases, infusion-related symptoms occur during the infusion or within 24 h of administration. Monitor patients until all signs and symptoms completely resolve. Consider discontinuation of therapy for patients who develop anaphylaxis, pulmonary edema, or acute respiratory distress syndrome. Patients with high peripheral blast counts may be at greater risk for pulmonary reactions and tumor lysis syndrome. Consider leukoreduction prior to administration for patients with high peripheral blast counts.Hepatotoxicity
Severe and sometimes fatal hepatic venoocclusive disease has been reported with use. Increased risk in patients with hematopoietic stem-cell transplants, underlying liver disease, or abnormal liver function, and in patients receiving adjunctive chemotherapy.Myelosuppression
Severe myelosuppression will occur in all patients given the recommended dose of this agent. Careful hematologic monitoring is required.
Monitor vital signs during infusion and for 4 h following infusion. Monitor electrolytes, hepatic function, CBCs, and platelet counts during therapy.
Category D .
Undetermined. Because many drugs, including immunoglobulins, are excreted in breast milk, and because of the potential for serious adverse reactions in breast-feeding infants from gemtuzumab ozogamicin, decide whether to discontinue breast-feeding or the drug, taking into account the importance of the drug to the mother.
Safety and efficacy not studied.
Not studied in adult patients with renal function impairment. Use with caution.
Not studied in patients with a bilirubin more than 2 mg/dL. Use with caution. Exercise caution when administering in patients with hepatic function impairment.
Infusion may be slowed or continued at the same rate if patient experiences a reaction. Interrupt infusion for dyspnea or profound hypotension. Symptoms may be treated with diphenhydramine (eg, Benadryl ), acetaminophen (eg, Tylenol ), bronchodilators, or IV fluids. Monitor the patient until symptoms resolve completely. Patients who react to the initial infusion may receive a second dose. Infusion duration may be increased at the health care provider's discretion.
Reduce incidence of infusion reactions with premedication. Give acetaminophen 650 to 1,000 mg (oral or rectal) and diphenhydramine 50 mg (oral or IV) 60 min before administering gemtuzumab ozogamicin.
May be a consequence of leukemia treatment. Take appropriate measures (eg, allopurinol, hydration) to prevent hyperuricemia.
No cases of overdose have been reported. Signs of overdose are unknown.
Copyright © 2009 Wolters Kluwer Health.